Spesana

Spesana has developed a proprietary healthcare platform that simplifies and automates the complex workflow of precision medicine. The platform interfaces with health systems' electronic medical records (EMRs) to consolidate clinical data, lab information, and financial systems, creating a unified view of the healthcare system's performance across clinical, operational, and financial aspects.

The multi-specialty platform is designed to facilitate timely, high-quality, and value-based patient care. It automates instant patient referrals, second opinions, provides relevant scientific articles and clinical knowledgebases to support specialists treating patients across multiple therapeutic areas. The platform also features a fully digital tumor board that eliminates manual data entry, ensuring more patients receive multi-disciplinary review of treatment or clinical trial decisions.

Spesana's platform allows physicians, patients, and insurance teams to collaborate on identifying the best available therapies and pathways for patients based on molecular diagnostics-driven decision support. The company was founded by oncology information technology trailblazer Carla Balch and a team known for building the first certified EMR platform in oncology.

In March 2022, Spesana appointed John Verniero as Chief Business Officer, Court Veach as Vice President of Sales, and Allen Rasoul as Vice President of Strategic Business Development to support its commercial growth phase. The company also formed an advisory board in May 2023, comprising industry leaders across clinical sites, life science companies, and diagnostic labs, to collaborate on strategies for leveraging the platform across various healthcare stakeholders.

Key customers and partnerships

In December 2023, Spesana announced a strategic partnership with FamGenix, a provider of hereditary risk screening solutions, to integrate FamGenix's offerings into Spesana's clinical workflow ecosystem. This collaboration aims to enhance clinicians' ability to make informed treatment decisions by providing a comprehensive suite of genomics insights and tools.

Additionally, in August 2023, Spesana partnered with Decode Health, a health-tech company specializing in AI and machine learning, to advance point-of-care solutions using Decode Health's data platform. This partnership aims to revolutionize patient care by providing clinicians with actionable data and insights at the point of care.